Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy

New England Journal of Medicine

Volumn 372, Issue 10, 2015, Pages 923-932

  Moore, Halle C F ^a   Unger, Joseph M ^b   Phillips, Kelly Anne ^d,e,h   Boyle, Frances ^f,g   Hitre, Erika ⁱ   Porter, David ^j   Francis, Prudence A ^d,e,h   Goldstein, Lori J ^k   Gomez, Henry L ^l   Vallejos, Carlos S ^m   Partridge, Ann H ⁿ   Dakhil, Shaker R ^p   Garcia, Agustin A ^r   Gralow, Julie ^c   Lombard, Janine M ^f   Forbes, John F ^e,f   Martino, Silvana ^s   Barlow, William E ^b   Fabian, Carol J ^q   Minasian, Lori ^u   Meyskens, Frank L ^t   Gelber, Richard D ^n,o   Hortobagyi, Gabriel N ^v   Albain, Kathy S ^w   more..

^a TAUSSIG CANCER INSTITUTE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e Australian New Zealand Breast Cancer Trials Group   (Australia)

^f CALVARY MATER NEWCASTLE HOSPITAL   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

^h International Breast Cancer Study Group   (Switzerland)

ⁱ NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^j Auckland District Health Board   (New Zealand)

^k FOX CHASE CANCER CENTER   (United States)

^l INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^m National Cancer Institute INEN and Oncosalud   (Peru)

ⁿ DANA FARBER CANCER INSTITUTE   (United States)

^o IBCSG Statistical Center   (United States)

^p WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^q UNIVERSITY OF KANSAS   (United States)

^r UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^s Angeles Clinic and Research Institute   (United States)

^t UNIVERSITY OF CALIFORNIA   (United States)

^u NATIONAL CANCER INSTITUTE   (United States)

^v UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^w LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FOLLITROPIN; GOSERELIN; ANTINEOPLASTIC AGENT; GONADORELIN;

ADULT; AGE DISTRIBUTION; ARTHRALGIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER FATIGUE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE CONTROL; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEADACHE; HOT FLUSH; HUMAN; HYPERHIDROSIS; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MENSTRUAL IRREGULARITY; MIDDLE AGED; MONOTHERAPY; MYALGIA; OUTCOME ASSESSMENT; OVARY INSUFFICIENCY; OVERALL SURVIVAL; POSTMENOPAUSE; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; RESTLESSNESS; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT PLANNING; VAGINAL DRYNESS; ADJUVANT CHEMOTHERAPY; AGONISTS; BREAST NEOPLASMS; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; MORTALITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PREGNANCY RATE; PREMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; GONADOTROPIN-RELEASING HORMONE; GOSERELIN; HUMANS; MIDDLE AGED; PREGNANCY; PREGNANCY RATE; PREMENOPAUSE; PRIMARY OVARIAN INSUFFICIENCY; REGRESSION ANALYSIS;

EID: 84924455746     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1413204     Document Type: Article

References (23)

1. Ruddy KJ, Gelber SI, Tamimi RM, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol 2014; 32: 1151-6.
2. Senkus E, Gomez H, Dirix L, et al. Attitudes of young patients with breast cancer toward fertility loss related to adjuvant systemic therapies. EORTC study 10002 BIG 3-98. Psychooncology 2014; 23: 173-82.
3. Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L. Utility of gonadotropin- releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol 2013; 24: 2224-35.
4. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011; 306: 269-76.
5. Oktay K, Sönmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy- induced gonadal injury. Oncologist 2007; 12: 1055-66.
6. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) v3.0 (http://ctep.cancer.gov/protocolDevelopment/electronic -applications/docs/ctcaev3.pdf).
7. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy- induced ovarian damage: prospective randomized study. Fertil Steril 2009; 91: 694-7.
8. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009; 117: 561-7.
9. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011; 29: 2334-41.
10. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin- releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012; 30: 533-8.
11. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol 2013; 121: 78-86.
12. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy- induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014; 40: 675-83.
13. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006; 24: 2917-31.
14. Buchholz S, Seitz S, Schally AV, et al. Triple-negative breast cancers express receptors for luteinizing hormone-releasing hormone (LHRH) and respond to LHRH antagonist cetrorelix with growth inhibition. Int J Oncol 2009; 35: 789-96.
15. Gründker C, Föst C, Fister S, Nolte N, Günthert AR, Emons G. Gonadotropinreleasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo. Breast Cancer Res 2010; 12: R49.
16. Schubert A, Hawighorst T, Emons G, Gründker C. Agonists and antagonists of GnRH-I and-II reduce metastasis formation by triple-negative human breast cancer cells in vivo. Breast Cancer Res Treat 2011; 130: 783-90.
17. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from Intergroup trial 0100 (SWOG-8814). Presented in part at the ASCO annual meeting, Orlando, FL, May 18-21, 2002. abstract.
18. Albain KS, Barlow WE, Ravdin PM, et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 2055-63.
19. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer 1998; 34: 632-40.
20. Poikonen P, Saarto T, Elomaa I, Joensuu H, Blomqvist C. Prognostic effect of amenorrhoea and elevated serum gonadotropin levels induced by adjuvant chemotherapy in premenopausal node-positive breast cancer patients. Eur J Cancer 2000; 36: 43-8.
21. Swain SM, Jeong JH, Geyer CE Jr, et al. Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med 2010; 362: 2053-65.
22. Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014; 371: 107-18.
23. Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015; 372: 436-46.